Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Boyer Website

Paul L. Boyer, Ph.D.

Selected Publications
1)  Gao L, Hanson MN, Balakrishnan M, Boyer PL, Roques BP, Hughes SH, Kim B, Bambara RA.
Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect.
J. Biol. Chem. 283: 9196-205, 2008. [Journal]
2)  Comin MJ, Vu BC, Boyer PL, Liao C, Hughes SH, Marquez VE.
D-(+)-iso-methanocarbathymidine: a high-affinity substrate for herpes simplex virus 1 thymidine kinase.
ChemMedChem. 3: 1129-34, 2008. [Journal]
3)  Das K, Sarafianos SG, Clark AD, Boyer PL, Hughes SH, Arnold E.
Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
J. Mol. Biol. 365: 77-89, 2007. [Journal]
4)  Boyer PL, Stenbak CR, Hoberman D, Linial ML, Hughes SH.
In vitro fidelity of the prototype primate foamy virus (PFV) RT compared to HIV-1 RT.
Virology. 367: 253-64, 2007. [Journal]
5)  Boyer PL, Julias JG, Ambrose Z, Siddiqui MA, Marquez VE, Hughes SH.
The nucleoside analogs 4'C-methyl thymidine and 4'C-ethyl thymidine block DNA synthesis by wild-type HIV-1 RT and excision proficient NRTI resistant RT variants.
J. Mol. Biol. 371: 873-82, 2007. [Journal]
6)  Boyer P, Clark P, Hughes S, Linial M, Rinke C, inventor; DHHS, assignee.
Foamy Virus Mutant Reverse Transcriptase.
Patent Pending, Filed in 2001. Application No. 0/478,442. Pending [Patent]

This page was last updated on 7/25/2008.